Addressing large, unmet global markets with innovative proprietary products More »
Capitalizing on high-value, emerging markets for pharmaceutical and diagnostic products More »
Identifying early-stage companies with potential to increase value for shareholders More »
GeneDx Announces Completion of 100,000 Exome Sequences more »
OPKO Health Completes Enrollment in Phase 2b Study of OPK88003 to Treat Type 2 Diabetes and Obesity more »
OPKO Plans to Address Draft Local Coverage Determination Published by Novitas Solutions for 4Kscore Test more »
OPKO Health is an opportunistic research and development company that targets large, high-growth markets.
FDA Approves New Drug Application for RAYALDEE® to Treat Secondary Hyperparathyroidism Associated with Vitamin D Insufficiency in Stage 3-4 Chronic Kidney Disease click here »